RECRUITING

Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

Talk to us

Conditions

Alpha-1 Antitrypsin DeficiencyAAT DeficiencyAATDCystic Fibrosis (CF)MacrophageCystic Fibrosis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.

Official Title

The Role of Conformational Diseases on Macrophage Function

Quick Facts

Study Start:2007-08-09
Study Completion:2033-07-20
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT01851642

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Signed informed consent
  2. * Male or female 18 years of age or older
  3. * Negative pregnancy test for women of childbearing potential
  4. * Hemoglobin \>12.5 g/dl measured on the day of participation
  5. * Negative urine nicotine test
  1. * Pregnancy or breastfeeding
  2. * Weight \< 50 kg
  3. * History of anemia requiring blood transfusions, erythropoietin supplementation, or iron supplementation within the past 36 months
  4. * Known hemoglobin \<12.5 g/dl within the past 90 days
  5. * Systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \>100 mmHg
  6. * Poor venous access
  7. * Large volume blood donation (\>200 ml or 7 ounces) within the previous 56 days (e.g. blood donation for the purposes of blood banking)
  8. * Clinically significant cardiac, hemostatic or neurological impairment or any other significant medical condition that, in the opinion of the investigator would affect subject safety (e.g., recent myocardial infarction, history of prolonged bleeding time, cerebral vascular accident, advanced cancer or uncontrolled medical condition)
  9. * Psychiatric or cognitive disturbance or illness that would affect subject safety
  10. * Current smoker

Contacts and Locations

Study Contact

Allison E. Faunce, B.A.
CONTACT
352-273-8666
Allison.Faunce@medicine.ufl.edu
Michelle Owens, RN, BSN
CONTACT
352-273-6339
Sandra.Owens@medicine.ufl.edu

Principal Investigator

Karina Serban, MD
PRINCIPAL_INVESTIGATOR
University of Florida, College of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine

Study Locations (Sites)

Shands at the University of Florida
Gainesville, Florida, 32610
United States

Collaborators and Investigators

Sponsor: University of Florida

  • Karina Serban, MD, PRINCIPAL_INVESTIGATOR, University of Florida, College of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2007-08-09
Study Completion Date2033-07-20

Study Record Updates

Study Start Date2007-08-09
Study Completion Date2033-07-20

Terms related to this study

Keywords Provided by Researchers

  • Macrophage
  • Alpha-1 Antitrypsin Deficiency
  • Cystic Fibrosis

Additional Relevant MeSH Terms

  • Alpha-1 Antitrypsin Deficiency
  • AAT Deficiency
  • AATD
  • Cystic Fibrosis (CF)